Clinical Trials
66 trialsN2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
SAFE-CAP
Yale University
The Auxiliary Effect of Artificial Intelligence in the Detection of Precancerous Lesions in Proximal Colon Cancer
Hebei Medical University Fourth Hospital
Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib
Hubei Cancer Hospital
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
Memorial Sloan Kettering Cancer Center
Immunobiome
University of Aarhus
A Study of Colesevelam for Lenalidomide-Associated Diarrhea
Memorial Sloan Kettering Cancer Center
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
FMT-TP
Second Affiliated Hospital, School of Medicine, Zhejiang University
Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy
Federal University of Minas Gerais
AIP2021
Fundació Sant Joan de Déu
XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)
Guangzhou University of Traditional Chinese Medicine
PROCAR-BQ
Jules Bordet Institute
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
City of Hope Medical Center
ASF-BC
Uppsala University Hospital
L. Plantarum 299v and Gut Microbiome, Diarrhoea, and Clostridioides Difficile Infection in Colorectal Cancer Patients
Medical University of Gdansk
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Eastern Cooperative Oncology Group
Loop
Philipps University Marburg
NET-PACS
Big Ten Cancer Research Consortium
Prevention of Irinotecan Induced Diarrhea by Probiotics
S&D Pharma SK s.r.o.
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
University of Kentucky
ELECT
Ipsen
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Celgene
SALFLADMET
Uppsala University Hospital
Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients
St. Jude Children's Research Hospital
Lactobacillus Rhamnosus in Prevention of Chemotherapy-related Diarrhoea
University of Helsinki
The Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure
Shiraz University of Medical Sciences
The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon
University of Aarhus
PRISME
Assistance Publique - Hôpitaux de Paris
Effect of the Use of Symbiotics in Patients With Colon Cancer
Federal University of Minas Gerais
Prevention and Treatment of Pyrrolitinib-associated Diarrhea
Tianjin Medical University Cancer Institute and Hospital
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Children's Oncology Group
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
M.D. Anderson Cancer Center
Low-Residue Diet in Treating Diarrhea in Patients Receiving Pelvic Radiation Therapy.
Case Comprehensive Cancer Center
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
Alliance for Clinical Trials in Oncology
Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors
Catholic University of the Sacred Heart
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
AHS Cancer Control Alberta
Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy
Johns Hopkins University
CASAD for Severe Diarrhea in the Emergency Department
M.D. Anderson Cancer Center
DEKOR
Johann Wolfgang Goethe University Hospital
FOCCUS
Royal Marsden NHS Foundation Trust
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
St. Jude Children's Research Hospital
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Celgene Corporation
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Alliance for Clinical Trials in Oncology
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy
Alliance for Clinical Trials in Oncology